Estimating the concentration of therapeutic range using disease-specific iPS cells: Low-dose rapamycin therapy for Pendred syndrome

Makoto Hosoya, Tsubasa Saeki, Chika Saegusa, Tatsuo Matsunaga, Hideyuki Okano, Masato Fujioka, Kaoru Ogawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Pendred syndrome is an autosomal-recessive disease characterized by congenital hearing loss and thyroid goiter. Previously, cell stress susceptibilities were shown to increase in patient-derived cells with intracellular aggregation using an in vitro acute cochlear cell model derived from patient-specific pluripotent stem (iPS) cells. Moreover, we showed that rapamycin can relieve cell death. However, studies regarding long-term cell survival without cell stressors that mimic the natural course of disease or the rational minimum concentration of rapamycin that prevents cell death are missing. Methods: In this report, we first investigated the rational minimum concentration of rapamycin using patient-specific iPS cells derived-cochlear cells with three different conditions of acute stress. We next confirmed the effects of rapamycin in long-term cell survival and phenotypes by using cochlear cells derived from three different patient-derived iPS cells. Results: We found that inner ear cells derived from Pendred syndrome patients are more vulnerable than those from healthy individuals during long-term culturing; however, this susceptibility was relieved via treatment with low-dose rapamycin. The slow progression of hearing loss in patients may be explained, in part, by the vulnerability observed in patient cells during long-term culturing. We successfully evaluated the rational minimum concentration of rapamycin for treatment of Pendred syndrome. Conclusion: Our results suggest that low-dose rapamycin not only decreases acute symptoms but may prevent progression of hearing loss in Pendred syndrome patients.

Original languageEnglish
Pages (from-to)54-63
Number of pages10
JournalRegenerative Therapy
Volume10
DOIs
Publication statusPublished - 2019 Jun 1

Fingerprint

Audition
Sirolimus
Cell death
Cells
Stem cells
Cochlea
Hearing Loss
Therapeutics
Agglomeration
Cell Survival
Cell Death
Pendred syndrome
Pluripotent Stem Cells
Goiter
Inner Ear
Thyroid Gland
Phenotype

Keywords

  • Hereditary hearing loss
  • Induced pluripotent stem cell
  • Pendred syndrome

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Developmental Biology

Cite this

Estimating the concentration of therapeutic range using disease-specific iPS cells : Low-dose rapamycin therapy for Pendred syndrome. / Hosoya, Makoto; Saeki, Tsubasa; Saegusa, Chika; Matsunaga, Tatsuo; Okano, Hideyuki; Fujioka, Masato; Ogawa, Kaoru.

In: Regenerative Therapy, Vol. 10, 01.06.2019, p. 54-63.

Research output: Contribution to journalArticle

@article{d1bdd0e88d504e9da740f7977bb2cdf6,
title = "Estimating the concentration of therapeutic range using disease-specific iPS cells: Low-dose rapamycin therapy for Pendred syndrome",
abstract = "Introduction: Pendred syndrome is an autosomal-recessive disease characterized by congenital hearing loss and thyroid goiter. Previously, cell stress susceptibilities were shown to increase in patient-derived cells with intracellular aggregation using an in vitro acute cochlear cell model derived from patient-specific pluripotent stem (iPS) cells. Moreover, we showed that rapamycin can relieve cell death. However, studies regarding long-term cell survival without cell stressors that mimic the natural course of disease or the rational minimum concentration of rapamycin that prevents cell death are missing. Methods: In this report, we first investigated the rational minimum concentration of rapamycin using patient-specific iPS cells derived-cochlear cells with three different conditions of acute stress. We next confirmed the effects of rapamycin in long-term cell survival and phenotypes by using cochlear cells derived from three different patient-derived iPS cells. Results: We found that inner ear cells derived from Pendred syndrome patients are more vulnerable than those from healthy individuals during long-term culturing; however, this susceptibility was relieved via treatment with low-dose rapamycin. The slow progression of hearing loss in patients may be explained, in part, by the vulnerability observed in patient cells during long-term culturing. We successfully evaluated the rational minimum concentration of rapamycin for treatment of Pendred syndrome. Conclusion: Our results suggest that low-dose rapamycin not only decreases acute symptoms but may prevent progression of hearing loss in Pendred syndrome patients.",
keywords = "Hereditary hearing loss, Induced pluripotent stem cell, Pendred syndrome",
author = "Makoto Hosoya and Tsubasa Saeki and Chika Saegusa and Tatsuo Matsunaga and Hideyuki Okano and Masato Fujioka and Kaoru Ogawa",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.reth.2018.11.001",
language = "English",
volume = "10",
pages = "54--63",
journal = "Regenerative Therapy",
issn = "2352-3204",
publisher = "Japanese Society of Regenerative Medicine",

}

TY - JOUR

T1 - Estimating the concentration of therapeutic range using disease-specific iPS cells

T2 - Low-dose rapamycin therapy for Pendred syndrome

AU - Hosoya, Makoto

AU - Saeki, Tsubasa

AU - Saegusa, Chika

AU - Matsunaga, Tatsuo

AU - Okano, Hideyuki

AU - Fujioka, Masato

AU - Ogawa, Kaoru

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Introduction: Pendred syndrome is an autosomal-recessive disease characterized by congenital hearing loss and thyroid goiter. Previously, cell stress susceptibilities were shown to increase in patient-derived cells with intracellular aggregation using an in vitro acute cochlear cell model derived from patient-specific pluripotent stem (iPS) cells. Moreover, we showed that rapamycin can relieve cell death. However, studies regarding long-term cell survival without cell stressors that mimic the natural course of disease or the rational minimum concentration of rapamycin that prevents cell death are missing. Methods: In this report, we first investigated the rational minimum concentration of rapamycin using patient-specific iPS cells derived-cochlear cells with three different conditions of acute stress. We next confirmed the effects of rapamycin in long-term cell survival and phenotypes by using cochlear cells derived from three different patient-derived iPS cells. Results: We found that inner ear cells derived from Pendred syndrome patients are more vulnerable than those from healthy individuals during long-term culturing; however, this susceptibility was relieved via treatment with low-dose rapamycin. The slow progression of hearing loss in patients may be explained, in part, by the vulnerability observed in patient cells during long-term culturing. We successfully evaluated the rational minimum concentration of rapamycin for treatment of Pendred syndrome. Conclusion: Our results suggest that low-dose rapamycin not only decreases acute symptoms but may prevent progression of hearing loss in Pendred syndrome patients.

AB - Introduction: Pendred syndrome is an autosomal-recessive disease characterized by congenital hearing loss and thyroid goiter. Previously, cell stress susceptibilities were shown to increase in patient-derived cells with intracellular aggregation using an in vitro acute cochlear cell model derived from patient-specific pluripotent stem (iPS) cells. Moreover, we showed that rapamycin can relieve cell death. However, studies regarding long-term cell survival without cell stressors that mimic the natural course of disease or the rational minimum concentration of rapamycin that prevents cell death are missing. Methods: In this report, we first investigated the rational minimum concentration of rapamycin using patient-specific iPS cells derived-cochlear cells with three different conditions of acute stress. We next confirmed the effects of rapamycin in long-term cell survival and phenotypes by using cochlear cells derived from three different patient-derived iPS cells. Results: We found that inner ear cells derived from Pendred syndrome patients are more vulnerable than those from healthy individuals during long-term culturing; however, this susceptibility was relieved via treatment with low-dose rapamycin. The slow progression of hearing loss in patients may be explained, in part, by the vulnerability observed in patient cells during long-term culturing. We successfully evaluated the rational minimum concentration of rapamycin for treatment of Pendred syndrome. Conclusion: Our results suggest that low-dose rapamycin not only decreases acute symptoms but may prevent progression of hearing loss in Pendred syndrome patients.

KW - Hereditary hearing loss

KW - Induced pluripotent stem cell

KW - Pendred syndrome

UR - http://www.scopus.com/inward/record.url?scp=85058463215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058463215&partnerID=8YFLogxK

U2 - 10.1016/j.reth.2018.11.001

DO - 10.1016/j.reth.2018.11.001

M3 - Article

AN - SCOPUS:85058463215

VL - 10

SP - 54

EP - 63

JO - Regenerative Therapy

JF - Regenerative Therapy

SN - 2352-3204

ER -